EUVIMEDEUVIMED entdecken
LeitlinieKohortenstudieOpen Access · CC BY 4.0

Real‐world treatment trajectories preceding GLP ‐1 receptor agonist initiation in type 2 diabetes: A descriptive UK population‐based cohort study on adherence to national clinical guidelines

Franziska S Ulrich iD, Morten Frost Nielsen iD, Nicola Napoli iD, Andrea M Burden iD

Diabetes, Obesity and Metabolism · 2026-05 · 28 (5) · 3692-3702

DOI: 10.1111/dom.70548 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 25.02.2026. Verfasst von Franziska S Ulrich und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Guideline Adherence. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Foundation for Medical-Biological Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To investigate glucose‐lowering treatment trajectories preceding glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) initiation in UK primary care, while assessing alignment with contemporary UK clinical guidelines, considering calendar time, cardiovascular disease (CVD) history, and obesity status. Materials and Methods Using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, a Cegedim Database, we included adults with type 2 diabetes initiating GLP‐1RAs in UK primary care between 01 January 2007 and 30 June 2023. We described treatment trajectories from the first glucose‐lowering therapy to GLP‐1RA initiation, stratified by calendar time (GLP‐1RA initiation pre‐ or post‐01 January 2018, when guidelines started recommending sodium‐glucose co‐transporter‐2 inhibitors [SGLT‐2is] for those at high risk or established CVD), CVD history, and body mass index (BMI) ≥35 kg/m 2 .

Results

We included 29 780 GLP‐1RA initiators, with 62.2% ( n = 18 517) initiating pre‐2018 and 37.8% ( n = 11 263) post‐2018. Consistent over calendar time, most GLP‐1RA initiators (63.5%) received their first GLP‐1RA as fourth‐line (35.4%) or later‐line therapy (28.1%), with fewer initiating GLP‐1RAs as first‐ (0.8%), second‐ (10.5%), or third‐line (25.2%) treatments. After 2018, 50.8% of individuals initiating GLP‐1RA therapy used SGLT‐2is concomitantly, regardless of CVD status (47.8% with established CVD vs. 51.5% without). Individuals with BMI ≥35 kg/m 2 initiated GLP‐1RA therapy earlier compared to those with BMI

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsGuideline AdherenceHumansUnited KingdomFemaleMaleMiddle AgedPractice Guidelines as TopicAgedSodium-Glucose Transporter 2 InhibitorsCardiovascular DiseasesCohort StudiesPrimary Health Care

Stichwörter der Autor:innen

GLP‐1 receptor agonistUnited Kingdomcardiovascular diseaseclinical guidancedrug utilisationglucose‐lowering therapyobesityprimary carereal‐world evidencetype 2 diabetes

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.
  • Department of Endocrinology, Odense University Hospital, Odense, Denmark.
  • Steno Diabetes Centre Odense, Odense University Hospital, Odense, Denmark.
  • Unit of Endocrinology and Diabetes, Campus Bio-Medico University of Rome, Rome, Italy.
  • Unit of Metabolic Bone and Thyroid Disorders, Fondazione Policlinico Universitario Campus Bio-Medico University of Rome, Rome, Italy.
  • Division of Bone and Mineral Diseases, Washington University, St Louis, Missouri, USA.

ORCID-Profile: Franziska S Ulrich, Morten Frost Nielsen, Nicola Napoli, Andrea M Burden

Förderung

  • Novartis Foundation for Medical-Biological Research

Zitieren

APA

Ulrich, F. S., Frost Nielsen, M., Napoli, N., & Burden, A. M. (2026). Real‐world treatment trajectories preceding GLP ‐1 receptor agonist initiation in type 2 diabetes: A descriptive UK population‐based cohort study on adherence to national clinical guidelines. Diabetes, Obesity and Metabolism, 28(5), 3692-3702. https://doi.org/10.1111/dom.70548

Vancouver

Ulrich FS, Frost Nielsen M, Napoli N, Burden AM. Real‐world treatment trajectories preceding GLP ‐1 receptor agonist initiation in type 2 diabetes: A descriptive UK population‐based cohort study on adherence to national clinical guidelines. Diabetes, Obesity and Metabolism. 2026;28(5):3692-3702. doi:10.1111/dom.70548

BibTeX
@article{Ulrich2026,
  author = {Ulrich, Franziska S and Frost Nielsen, Morten and Napoli, Nicola and Burden, Andrea M},
  title = {Real‐world treatment trajectories preceding GLP ‐1 receptor agonist initiation in type 2 diabetes: A descriptive UK population‐based cohort study on adherence to national clinical guidelines},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {5},
  pages = {3692--3702},
  doi = {10.1111/dom.70548}
}
Kostenlos starten →